Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs

Malcolm S Duthie, Bruna A S Machado, Roberto Badaró, Paul M Kaye, Steven G Reed

Research output: Contribution to journalReview articlepeer-review


Leishmania parasites cause a variety of discrete clinical diseases that present in regions where their specific sand fly vectors sustain transmission. Clinical and laboratory research indicate the potential of immunization to prevent leishmaniasis and a wide array of vaccine candidates have been proposed. Unfortunately, multiple factors have precluded advancement of more than a few Leishmania targeting vaccines to clinical trial. The recent maturation of RNA vaccines into licensed products in the context of COVID-19 indicates the likelihood of broader use of the technology. Herein, we discuss the potential benefits provided by RNA technology as an approach to address the bottlenecks encountered for Leishmania vaccines. Further, we outline a variety of strategies that could be used to more efficiently evaluate Leishmania vaccine efficacy, including controlled human infection models and initial use in a therapeutic setting, that could prioritize candidates before evaluation in larger, longer and more complicated field trials.

Original languageEnglish
Article number1259
Number of pages12
JournalPathogens (Basel, Switzerland)
Issue number11
Publication statusPublished - 29 Oct 2022

Bibliographical note

© 2022 by the authors

Cite this